Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

Aileron Therapeutics logo

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.75
$3.93
52-Week Range
N/A
Volume
63,385 shs
Average Volume
81,188 shs
Market Capitalization
$45.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

Aileron Therapeutics Rebrands As Rein Therapeutics
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

ALRN Stock Analysis - Frequently Asked Questions

Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.20.

Shares of Aileron Therapeutics reverse split on the morning of Thursday, November 10th 2022.The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

Last Earnings
8/14/2024
Today
7/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALRN
CIK
1420565
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.73 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-74.08%
Return on Assets
-27.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.30
Quick Ratio
3.30

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
21,670,000
Free Float
20,561,000
Market Cap
$45.72 million
Optionable
Not Optionable
Beta
2.24

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:ALRN) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners